SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma.

SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma.
复制标题

DOI:
10.18632/oncotarget.9461
复制
发表时间:
2016-06-28
期刊:
影响因子:
--
通讯作者:
He JX
He JX
中科院分区:
其他
文献类型:
--
作者:
Huang J;Fan XX;He J;Pan H;Li RZ;Huang L;Jiang Z;Yao XJ;Liu L;Leung EL;He JX

文献摘要

参考文献

被引文献

相似文献

沃伯格效应的发现开启了抗癌治疗的新纪元。有氧糖酵解被认为是癌细胞的一个标志,越来越多的文献表明代谢变化对癌细胞的维持和发展至关重要。除了有氧糖酵解外,癌细胞的快速生长还需要增加脂肪酸的合成,也被认为是癌症最典型的代谢标志之一。因此,靶向脂肪酸代谢可能为癌症的诊断和治疗提供了一条潜在的途径。在本研究中,我们鉴定出Sterol-CoA desaturase-1 (SCD1),它是不饱和脂肪酸合成的限速酶,在肺腺癌中普遍且高表达,是细胞增殖、迁移和侵袭所必需的。体外和体内研究均表明,高表达SCD1可显著增强肿瘤形成和侵袭能力,而低表达SCD1可显著抑制肿瘤发生并诱导细胞凋亡。临床关联研究提示SCD1高表达多见于晚期患者,预后较差。综上所述,我们的研究结果表明,SCD1是一种潜在的肺腺癌新生物标志物,靶向SCD1可能代表一种新的抗癌策略。
The discovery of Warburg effect opens a new era in anti-cancer therapy. Aerobic glycolysis is regarded as a hallmark of cancer cells and increasing literatures indicates that metabolic changes are critical for the maintenance and progression of cancer cells. Besides aerobic glycolysis, increased fatty acid synthesis is also required for the rapid growth of cancer cells, and is considered as one of the most typical metabolic symbols of cancer either. Thus, targeting fatty acid metabolism may provide a potential avenue for the diagnosis and therapeutic treatment of cancer. In this study, we have identified Sterol-CoA desaturase-1 (SCD1) which is the rate-limiting enzyme of unsaturated fatty acid synthesis, universally and highly expressed in lung adenocarcinoma and was required for the cell proliferation, migration and invasion. Both in vitro and in vivo studies demonstrated that high expression of SCD1 remarkably enhanced the ability of tumor formation and invasion, while knockdown of SCD1 significantly repressed tumorigenesis and induced cell apoptosis. Clinical association study suggested that high expression of SCD1 is more frequently observed in late stage patients and presents poor prognosis. Taken together, our results suggested that SCD1 is a potentially novel biomarker of lung adenocarcinoma, and targeting SCD1 may represent a new anti-cancer strategy.
DOI: 10.1007/s11523-013-0258-9
发表时间: 2013-03
期刊: TARGETED ONCOLOGY
影响因子: 5.4
作者:
Kobayashi, Kunihiko;Hagiwara, Koichi
通讯作者: Hagiwara, Koichi
DOI: 10.3390/molecules19033508
发表时间: 2014-03-21
期刊: Molecules (Basel, Switzerland)
影响因子: --
作者:
Fan XX;Li N;Wu JL;Zhou YL;He JX;Liu L;Leung EL
通讯作者: Leung EL
DOI: 10.1258/ebm.2012.012126
发表时间: 2012-09-01
影响因子: 3.2
作者:
Nashed, Mary;Chisholm, Jeffrey W.;Igal, R. Ariel
通讯作者: Igal, R. Ariel
DOI: 10.1371/journal.pone.0061204
发表时间: 2013
期刊: PloS one
影响因子: 3.7
作者:
Ide Y;Waki M;Hayasaka T;Nishio T;Morita Y;Tanaka H;Sasaki T;Koizumi K;Matsunuma R;Hosokawa Y;Ogura H;Shiiya N;Setou M
通讯作者: Setou M
DOI: 10.18632/oncotarget.2017
发表时间: 2014-07-15
期刊: Oncotarget
影响因子: --
作者:
Bokobza SM;Jiang Y;Weber AM;Devery AM;Ryan AJ
通讯作者: Ryan AJ